Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Sell
32
CCEL Quote, Financials, Valuation and Earnings
Last price:
$4.85
Seasonality move
:
13.88%
Day range:
$4.81 - $4.86
52-week range:
$4.75 - $9.50
Dividend yield:
10.4%
P/E ratio:
481.00x
P/S ratio:
1.23x
P/B ratio:
--
Volume:
3K
Avg. volume:
11.2K
1-year change:
-44.26%
Market cap:
$38.9M
Revenue:
$32M
EPS (TTM):
$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Cryo-Cell International has 76.72% upside to fair value with a price target of $8.50 per share.
CCEL vs. S&P 500
-
Over the past 5 trading days, Cryo-Cell International has underperformed the S&P 500 by -12.91% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cryo-Cell International does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cryo-Cell International has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Cryo-Cell International reported revenues of $8M.
Earnings Growth
-
Cryo-Cell International earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cryo-Cell International reported earnings per share of $0.03.
Enterprise value:
48.4M
EV / Invested capital:
-29.62x
Price / LTM sales:
1.23x
EV / EBIT:
10.42x
EV / Revenue:
1.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.77x
Price / Operating cash flow:
9.57x
Enterprise value / EBITDA:
8.28x
Gross Profit (TTM):
$24.3M
Return On Assets:
0.2%
Net Income Margin (TTM):
0.4%
Return On Equity:
--
Return On Invested Capital:
122.88%
Operating Margin:
13.25%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Income Statement | ||||||
| Revenue | $30.9M | -- | $32.1M | -- | $8M | |
| Gross Profit | $22.1M | -- | $24.3M | -- | $6M | |
| Operating Income | $4.6M | -- | $4M | -- | $1.1M | |
| EBITDA | $6.8M | -- | $5.8M | -- | $1.4M | |
| Diluted EPS | $0.32 | -- | $0.01 | -- | $0.03 | |
| Period Ending | 2021-02-28 | 2022-02-28 | 2023-02-28 | 2024-02-28 | 2025-02-28 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.7M | $9.7M | $10.6M | -- | $12.5M | |
| Total Assets | $105.3M | $54.8M | $66.1M | -- | $64.4M | |
| Current Liabilities | $29.8M | $16.4M | $18.9M | -- | $21.7M | |
| Total Liabilities | $107M | $50.6M | $66.8M | -- | $79M | |
| Total Equity | -$1.7M | $4.3M | -$687.5K | -- | -$14.7M | |
| Total Debt | $4.2M | $1.1M | $10.5M | -- | $13M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $8.7M | -- | $7.3M | -- | $954.1K | |
| Cash From Investing | -$10.4M | -- | -$4.8M | -- | -$287.5K | |
| Cash From Financing | $947K | -- | -$2.5M | -- | -$1M | |
| Free Cash Flow | -$3.2M | -- | $4.1M | -- | $892K | |
CCEL
Sector
Market Cap
$38.9M
$34.5M
Price % of 52-Week High
50.64%
43.57%
Dividend Yield
10.4%
0%
Shareholder Yield
7.29%
-0.79%
1-Year Price Total Return
-44.26%
-42.08%
Beta (5-Year)
0.724
0.660
Dividend yield:
10.4%
Annualized payout:
$0.25
Payout ratio:
3139.7%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.21
200-day SMA
Sell
Level
$7.02
Bollinger Bands (100)
Sell
Level
5.97 - 7.95
Chaikin Money Flow
Buy
Level
4.5M
20-day SMA
Sell
Level
$5.43
Relative Strength Index (RSI14)
Sell
Level
29.83
ADX Line
Sell
Level
25.15
Williams %R
Buy
Level
-95.3125
50-day SMA
Sell
Level
$6.18
MACD (12, 26)
Sell
Level
-0.34
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
13.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.3952)
Sell
CA Score
(Annual)
Level (-3.1115)
Buy
Beneish M-Score
(Annual)
Level (-2.7422)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-6.6059)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Stock Forecast FAQ
In the current month, CCEL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CCEL average analyst price target in the past 3 months is $8.50.
-
Where Will Cryo-Cell International Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cryo-Cell International share price will rise to $8.50 per share over the next 12 months.
-
What Do Analysts Say About Cryo-Cell International?
Analysts are divided on their view about Cryo-Cell International share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cryo-Cell International is a Sell and believe this share price will drop from its current level to $8.50.
-
What Is Cryo-Cell International's Price Target?
The price target for Cryo-Cell International over the next 1-year time period is forecast to be $8.50 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CCEL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cryo-Cell International is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CCEL?
You can purchase shares of Cryo-Cell International via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cryo-Cell International shares.
-
What Is The Cryo-Cell International Share Price Today?
Cryo-Cell International was last trading at $4.85 per share. This represents the most recent stock quote for Cryo-Cell International. Yesterday, Cryo-Cell International closed at $4.81 per share.
-
How To Buy Cryo-Cell International Stock Online?
In order to purchase Cryo-Cell International stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 15.23% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0.14% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 20.04% over the past day.
